相关实验视频

Updated: Jan 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

作为一个可向的免疫检查点枢纽的PDCD1:对ibrutinib耐药CLL管理的治疗见解

Niloufar Sadat Kalaki^1,2, Elham Karimi³, Kasra Allaei Rouzbahani^4,5

¹Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Clinical and experimental medicine

|November 17, 2025

概括

这项研究确定PDCD1是慢性淋巴细胞白血病 (CLL) 耐布鲁替尼抗性的关键基因. 将BTK抑制剂与免疫检查点阻塞相结合,可以克服CLL患者的耐药性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

慢性淋巴细胞白血病 (CLL) 涉及异常的淋巴细胞过度生产.
易布鲁替尼抗药性是CLL治疗的一个重大挑战.
了解耐药机制对于开发有效疗法至关重要.

研究的目的:

为了确定与CLL. ibrutinib耐药性相关的关键基因.
调查PDCD1在CLL耐药性的作用.
探索克服ibrutinib耐药性的潜在治疗策略.

主要方法:

使用两个独立的CLL数据集进行差异基因表达分析.
蛋白与蛋白相互作用 (PPI) 网络分析以确定枢纽基因.
为PDCD1.1构建竞争的内源RNA (ceRNA) 网络.
识别调节PDCD的转录因子1.
药物基因相互作用分析.

主要成果:

鉴定出PDCD1,CD1C和ITGB2是易布鲁替尼抗性CLL中常见的枢纽基因.
编码为PD-1的PDCD1在免疫调节和药物耐药性方面发挥着重要作用.
复杂的后转录和转录调节网络调节PDCD1的表达.
PDCD1涉及到CLL细胞中的免疫逃脱和增殖.

结论:

通过免疫检查点途径,PDCD1是通过免疫检查点途径在CLL中对ibrutinib耐药性的核心.
免疫检查点封锁是一种有希望的策略,可以克服CLL中的ibrutinib耐药性.
将BTK抑制剂与免疫检查点阻断相结合是对抗性CLL的合理治疗方法.

关键词:

慢性淋巴细胞白血病 (CLL) 是一种疾病.易布鲁丁尼布的耐药性耐药性免疫检查站检查站个人个人信息网络PPI网络.

更多相关视频

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...